1. 1 BioCancell Therapeutics, Inc. BioCancell Therapeutics An Innovative Cancer Treatment Approach December, 2009

2. 2 This presentation contains forward-looking statements within the meaning of the federal securities laws that involve risks and uncertainties. These forward-looking statements, relate to, without limitation, statements about our market opportunities, our strategy, our competition, the further development and potential safety and efficacy of our products, our projected revenue and expense levels and the adequacy of our available cash resources. This presentation also may contain forward-looking statements attributed to third parties relating to their estimates regarding our industry. You should not place undue reliance on any of the forward-looking statements contained in this presentation. Drug discovery and development involve a high degree of risk. Factors that might cause material differences include, among others, risks relating to: the successful preclinical development of our product candidates; the completion of clinical trials; the review process of the FDA, foreign regulatory bodies and other governmental regulation, including the FDA`s review of any filings we make in connection with the treatment protocol; delays in the FDA`s or other health regulatory authorities` approval of any applications we file or refusals to approve such filings; refusals by such regulatory authorities to approve the marketing and sale of a drug product even after acceptance of an application we file for any such drug product; the identification of lead compounds; the risk that we may fail to satisfy certain conditions relating to grants we have received from the Office of the Chief Scientist of Israel`s Ministry of Industry and Trade which may lead to our being required to refund grants previously received together with interest and penalties; the risk that the Office of the Chief Scientist may not deliver to us all of the funds awarded to us; uncertainties related to the ability to attract and retain partners for our technologies and products under development; and other factors described in our filings with the Securities and Exchange Commission. Although we believe that the expectations reflected in these forward-looking statements are based upon reasonable assumptions, no assurance can be given that such expectations will be attained or that any deviations will not be material. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We disclaim any obligation or undertaking to disseminate any updates or revision to any forward-looking statement contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Safe Harbor

3. 3 BioCancell Overview  Incorporated in Delaware (July 2004), 17 Employees  Developing innovative targeted drugs for the treatment of cancer, based on Professor Hochberg’s research  Lead product candidate BC-819 in advanced clinical trials: Phase IIb in bladder cancer, Phase I/IIa in pancreatic and ovarian cancers  Intellectual Property: 7 patent families  Listed on TASE (BICL) in Aug. 2006, SEC filing since June 2009  Fundraising: $14.5M, in private placements and IPO on TASE (TASE:BICL), grants: CSO ($1.8M) and BIRDF ($0.95M)  Major Stockholders: Clal Biotechnology Industries Ltd. (23.44%), Prof. Avraham Hochberg (13.09%), Tikcro (5.51%), Avi Barak (4.70%), Provident Fund of the Employees of the Hebrew University of Jerusalem Ltd. (3.99%)

4. 4 Technology Platform  Targeted treatment platform based on the H19 gene  H19 is a significant differentiator - expressed uniquely within cancer cells while not expressed in normal cells  BC-819 drug candidate use the H19 gene to activate the diphtheria toxin in cancer cells, which destroys the cancer cells, without affecting normal cells  The treatment is patient oriented and targeted without side effects*  Platform potential: H19 expressed in more than 40 different cancer indications *Detected to date

5. 5 After birth, H19 is expressed only in cancer cells, and is therefore a significant marker of cancer cells The expression of H19 in cancer cells promote tumor development

6. 6 The Drug - BC-819 Plasmid H19 Promoter Diphtheria Toxin sequence A DNA plasmid containing the H19 gene regulatory sequences that drive the expression of the Diphtheria Toxin A gene (DTA-H19)

7. 7 The Advantages of BC-819  Good safety profile – no side effects related to the drug*  Lack of side effects – prevents patient withdrawal (compared to chemotherapy treatment)  Reduces Multi-Drug Resistance (MDR) - a major disadvantage of chemotherapy  Targeted drug - yields superior success rate  Expected fast regulatory pathway (Fast-Track) - as FDA aims to promote new cancer treatments  Same drug for 40 different cancer types expressing H19  Low cost manufacturing vs. other biological products * Detected to date

8. 8 BC-819 Development Roadmap 2009201120122010 Ovarian cancer Pancreatic cancer Phase IIb Phase I/IIa Phase III FDA Meeting Phase IIb Phase I/IIa Phase III FDA Meeting Bladder cancer Phase IIb FDA Meeting Phase III All Indications are with Fast-Track Potential Phase I/IIa (was completed in 2007)

9. 9 Market Size – Treatment of Bladder Cancer New Cases* PrevalenceDeaths / Year H19 Expression ** (%) 175,0001,500,00037,00084% * Data: Globocan; World Population Prospects and American Cancer Society, estimated 2009. Data refers to the population in the 7 major pharmaceutical markets ** % of patients expressing H19 Competitors’ Drugs – Annual Sales Volume: BCG* (TheraCys/ TICE) – Sanofi-Aventis/ Schering-Plough Corp. (Organon Pharmaceuticals), $200M * Drug label present black box warning The cost per patient of bladder cancer from diagnosis to death is the highest of all cancers, ranging from $96K-$187K

10. 10 Market Size – Treatment of Ovarian Cancer New Cases* PrevalenceDeaths / Year H19 Expression ** (%) 60,000400,00040,00075% * Data: Globocan; World Population Prospects and American Cancer Society, estimated 2009. Data refers to the population in the 7 major pharmaceutical markets ** % of patients expressing H19 Competitors’ Drugs – Annual Sales Volume: Doxil/ Caelyx* - Johnson & Johnson/ Schering-Plough Corp, $650M (all indications) Taxotere* (Sanofi-Aventis), $3B (all indications) Hycamitin (GlaxoSmithKline), $325M (all indications) * Drug label present black box warning

11. 11 Market Size – Treatment of Pancreatic Cancer New Cases* Prevalence# of deaths per year H19 Expression ** (%) 100,00090,000 70% * Data: Globocan; World Population Prospects and American Cancer Society, estimated 2009. Data refers to the population in the 7 major pharmaceutical markets ** % of patients expressing H19 Competitors’ Drugs – Annual Sales Volume: Gemzar - Eli Lilly & Co, $1.72B (all indications) Tarceva (in combination with Gemzar) – OSI Pharmaceuticals /Genentech/Roche, $1.66B (all indications)

12. 12 Marketed Blockbuster Drugs - Sales Avastin – originally approved for colorectal cancer 20042005200620072008 $651M$1,571M$2,795M$3,875M$4,914M Herceptin - breast cancer, for “only” 40,000 potential patients 20042005200620072008 $3,188M$3,920M$4,567M$5,206M$5,590M (new approved indications, contributed to an increase in sales) Lung (NSCLC) RCC/EMEA HER2- negative breast cancer * Source: Data Monitor

13. 13  Lung Cancer (NSCLC): Tarceva (Erlotinib) - $1.66B  Liver Cancer: 5-Fluorouracil (Adrucil, Efudex, Fluoroplex) – Blockbuster  Kidney Cancer (RCC): Sorafenib (Nexavar) - $900M BC-819 – Additional Indications  BC-819 has been successfully tested in animals for the treatment of lung cancer, liver cancer and kidney cancer  Market potential (annual sales) for other drugs in those indications:

14. 14 Phase I/IIa in Bladder Cancer  Purpose - assess the safety and preliminary efficacy of BC-819  Performed at two medical centers in Israel  18 patients participated in the trial, who had failed treatment with standard treatments (BCG or chemotherapy)  The trial was successfully concluded in August 2007 Results: - No Serious Adverse Events related to BC-819 were detected - 55.6% (10/18 patients) did not experience recurrence of tumor - 94.4% (17/18 patients) did not experience progression

15. 15 Phase IIb in Bladder Cancer  Purpose – two stage design clinical study to assess the efficacy and safety of BC-819  Performed at seven medical centers in Israel and one in the US (BCG Oncology, Arizona)  Inclusion criteria - Refractory patients with TCC (recurrent stages Ta, T1, low grade) that is positive for H19, who have failed treatment with BCG or chemotherapy  Eligible patients will receive a six-week induction course of once-weekly intravesical administrations  33 patients will participate: At least 5 of first 18 evaluable patients must have a CR to meet the criteria to continue accrual of 15 additional evaluable patients

16. 16 Ovarian Cancer Compassionate Use Background: A 69 year-old female patient, failure of all available treatments, chemotherapy resistance Intraperitoneally treated with BC-819, in doses ranging from 80mg to 140mg After the treatment with BC-819: Extension of patient's life by 18 months beyond her original 3 month life-expectancy No SAEs were reported Tumor growth was arrested Cancer marker CA-125 dropped by ~50% Reduction of number of cancerous cells in patient’s ascitic fluid Ascitic fluid level was significantly reduced The patient and her physicians reported significant clinical improvement 31.10.07- before treatments 02.01.08- After treatment #8 (Ascites)

17. 17 Phase I/IIa in Ovarian Cancer  Purpose – determine safety and the optimal dose for intraperitoneal delivery of BC-819  Phase I/IIa, Dose-Escalation, Safety, Pharmacokinetic and Preliminary Efficacy Study  Performed in Israel and in the US (at the NCI-designated Massey Cancer Center and the University of Pennsylvania Medical Center)  12 patients with ovarian cancer to be treated  FDA granted ‘Orphan Drug’ status for BC-819 in the US, for treatment of ovarian cancer

18. 18 Animal Model for Pancreatic Cancer Primary pancreatic tumor ex vivo volume in hamsters treated with BC-819 was significantly reduced (50%) compared to the control group Only one third of the treated group showed metastatic growths, while all of the animals in the control group developed metastases

19. 19 Phase I/IIa in Pancreatic Cancer  Purpose – determine safety and the optimal dose of BC-819  Phase I/IIa, Dose-Escalation, Safety, Pharmacokinetic and Preliminary Efficacy Study  Performed in Israel and in the US (at the NCI-designated University of Maryland Medical Center and Massey Cancer Center)  9 patients with unresectable pancreatic cancer to be treated intratumorally 4 times with BC-819, twice a week for 2 weeks

20. 20 The 2nd Generation Drug - BC-821  Use of both the H19 and IGF2-P4 genes (double promoter plasmid) as a treatment platform for targeted treatment  Status: pre-clinical results in animals The drug covers 100% of the eligible cancer patients (30%-50% more than BC-819)

21. 21 Patent (granted) for BC-819 was submitted on October 1997 New patent application for BC-821 was submitted on October 2008 Other patent applications for additional technologies in pre- clinical research (si-RNA, etc.) Intellectual Property

22. 22 Priority date: 10/1997 Granted: USA, Europe, China, Korea, Russia, Singapore, the Czech Republic, Canada, Israel, Mexico and Australia Pending: Japan, Brazil, Hungary and Norway Expiration (without extension): 10/2017 – in US, 10/2018 – Worldwide Extension Strategies:  Orphan drugs (7 years) – already approved for ovarian cancer  Extension due to drug development process (up to 5 years)  Database protection (5-10 years)  New US legislation (up to 12 years) Patent Status for BC-819

23. 23 Management Avi Barak, Chairman –Former CEO of BioCancell (until Oct. 2009) and Yissum, the TTC of the Hebrew University –Former Director at Bezeq, Israel’s PTT, and Pelephone, Israel’s leading mobile carrier Uri Danon, CEO –Former CEO of Atox Bio and Epigenesis –Managed large-scale international projects, at Teva Pharmaceuticals Industries Ltd., including Copaxone in a pre-filled syringe Ira Weinstein, CFO & COO –Former CEO of Hapto Biotech (Israel) Ltd. and Incure Ltd. –Former CFO & COO of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX; and AIM:KRX) Prof. Avraham Hochberg, CSO, Founder –Professor of Biochemistry, Hebrew University, Jerusalem, Israel –The world-leading expert on H19 with over 140 publications Dr. Doron Amit, VP Business Development & IP –Former Director of US Funds Department and Chief Life Science Analyst at FreeMind Consulting Group –Leads the research and development of BioCancell’s 2nd generation drug - BC-821 Moshe Landsberg, CTO & VP QA –Former COO at BioPreventative Ltd (later Analyte Works Ltd) and QA and Operations Manager at Common Sense Ltd and Lithotech Medical Ltd –Former Special Projects Manager at Biotechnology General (Israel) Ltd Dr. Patricia Ohana, VP Clinical Development –A biochemist and molecular biologist at the Hebrew University of Jerusalem where she holds a position as research scientist in the Department of Biological Chemistry –Involved in many aspects of ground-breaking research on H19 gene, lead by Professor Hochberg

24. 24 SAB Members Prof. Avraham Hochberg, Ph.D., SAB Chairman –Founder & CSO –Professor of Biochemistry at the Hebrew University of Jerusalem –A recipient of the Kaye Award for innovation Aaron Ciechanover, M.D., Ph.D. –Nobel Prize Laureate in Chemistry, in 2004 –Distinguished Professor in the Faculty of Medicine and Research Institute at the Technion Roger D. Kornberg, Ph.D. –Nobel Prize Laureate in Chemistry, in 2006 –Professor of Structural Biology at Stanford University School of Medicine Yechezkel Barenholz, Ph.D. –Professor of Biochemistry at the Hebrew University of Jerusalem –Inventor of Doxil, an anticancer drug with annual sales of over $650 million Yaakov Naparstek, M.D. –Chairman of Medicine at Hadassah University Hospital Hermona Soreq, Ph.D. –Former Dean of the Faculty of Science at the Hebrew University of Jerusalem, Israel Mark L. Tykocinski, M.D. –Dean of Jefferson Medical College and Senior Vice President of Thomas Jefferson University –Former chairman of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania –President / Chair of two leading pathology associations in the US

25. 25 Short-Term Anticipated Events Recruitment of the second group of patients in the ovarian cancer Phase I/IIa clinical trial Completion of the first stage of the bladder cancer Phase IIb clinical trial ‘Orphan Drug’ designation for the treatment of bladder and pancreatic cancers ‘Fast-Track’ designation for the treatment of ovarian and pancreatic cancers Approval of the lead patent in additional countries

26. 26 Use of Proceeds to Increase Value BC-819 clinical trials:  Complete the ongoing clinical trials: phase IIb in bladder cancer, phase I/IIa in pancreatic and ovarian cancers  Phase IIb for either ovarian or pancreatic cancer  Strategic Alliance* for co-development of further clinical trials for bladder cancer and commercialization Complete pre-clinical studies with next-generation BC-821 and enter into phase I in NSCLC (lung) or brain cancer OTC/ NASDAQ listing * Strategic Alliance with a pharmaceutical company for co- development and commercialization for bladder cancer Investment of $15M will enable 2 years of operations to obtain the following milestones:

27. 27  H19: targeted gene, which has major role in cancer development and differentially expressed in over 40 types of cancer  Blockbuster potential indicate value - increase potential  Targeted treatment of cancer cells, without side effects*  All clinical trials are FDA-approved  Additional drugs in R&D (Double-Plasmid and si-RNA)  Strong IP position – worldwide filings  Leading interdisciplinary scientific team (7 Ph.D.’s) Summary *Detected to date

28. 28 Thank You Please visit us at www.biocancell.com www.biocancell.com